BOSTON, January 07, 2022–(BUSINESS WIRE)–908 devices (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSE: GSK) has purchased a REBEL™ cell culture media analyzer. GSK will now have a total of five REBEL analyzers used by its bioprocess and vaccine development teams.
“We are delighted that GSK has once again selected our REBEL desktop device as part of its process development efforts to bring promising therapies to market,” said Dr. Kevin J. Knopp, CEO and co-founder of 908 Devices. “The REBEL Analyzer enables our biopharma customers to make critical decisions about cell culture optimization in minutes, and its small desktop footprint fits alongside bioreactors in process development labs.”
908 Devices notes that there are now 15 customers with multiple REBEL devices, more than double the number a year ago. Additionally, 20 of the top 20 pharmaceutical companies now use the company’s desktop devices, which include REBEL and ZipChip®, in their development process.
About the REBEL Analyzer
REBEL is the first miniature CE-MS-based analyzer that enables biopharmaceutical researchers to accelerate process development cycles and maximize bioreactor utilization by performing in-line media analysis. Key benefits include:
Samples can be analyzed in minutes, eliminating basic lab wait times of days or even weeks.
Quantify over 30 components in cell culture media, including amino acids, dipeptides, water-soluble vitamins and amines.
Easy to use with an intuitive user interface and touchscreen, and the REBEL’s small footprint allows for flexibility in lab layout.
For more information, visit www.908devices.com.
About 908 devices
908 Devices Inc. (NASDAQ: MASS) is democratizing mass spectrometry in the lab with its simple, portable and desktop devices for mission-critical applications. The company’s devices are used to the point where they are needed to interrogate unknown and unseen materials and provide fast, actionable answers to directly solve some of the most critical problems in life science research, bioprocessing, pharmacy/biopharma, forensics and adjacent markets. The company is headquartered in the heart of Boston, where it designs and manufactures innovative products that combine the power of mass spectrometry, microfluidic separations, software automation and machine learning.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “plan”, “anticipate”, “believe”, “intention” and similar expressions (as well as other words or expressions referring to future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from the results expressed or implied by any forward-looking statement, including the risks described under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC’s website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other documents filed from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and assumes no obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as required by law. required.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220107005076/en/
PAN communications for 908 devices